Kinvey, Zink, ImmusanT, and More of this Week’s Boston Dealmakers
IT and life sciences companies around New England shared the deals news pool this week.
—Zink pinned down $35 million in a Series B round led by Genii Capital. The Bedford, MA-based company, whose name stands for “zero ink,” is developing technology for inkless printers that can connect to devices like digital cameras. Zink also announced that it had named two of its board members, Mary Jeffries and Ira Parker (both Polaroid veterans), as co-CEOs.
—Cambridge, MA-based Kinvey inked a partnership with Seattle-based Urban Airship, which powers push notifications for mobile apps. Kinvey, a 2011 TechStars Boston graduate, will provide the data back-end services for developers using Urban Airship’s notifications. Financial terms of the partnership weren’t disclosed.
—LifeImage, a Newton, MA-based developer of technology for sharing medical images over the Internet cloud, took in $8 million in equity financing from 13 investors, an SEC filing showed. The company’s previous investors include Galen Partners, Cardinal Partners, Long River Ventures, Massachusetts Technology Development Corporation, and Partners Innovation Fund.
—Vatera Healthcare Partners of New York put $20 million in Series A money into Cambridge-based ImmusanT a new biotech targeting celiac disease, a condition that renders gluten toxic in the body. The company is developing a vaccine that would make celiac disease patients tolerant to the toxic effects of gluten, and is also working on a test for diagnosing and monitoring the medical condition.